سعر اريبيبرازول 30مجم 20 قرص سريع الذوبان 2022

Aripiprazole 30 mg orally disintegrating tablets by El-Obour, an atypical antipsychotic marketed in Egypt; pack of 20 tablets (2 strips).

• SchizophreniaPopulation: Adults and adolescents 15 years and olderEuropean Medicines Agency (EPAR product information)
• Moderate to severe manic episodes in bipolar I disorder and prevention of new manic episodes in respondersPopulation: AdultsEuropean Medicines Agency (EPAR product information)
• Moderate to severe manic episodes in bipolar I disorder (up to 12 weeks)Population: Adolescents 13 years and olderEuropean Medicines Agency (EPAR product information)

• Most commonly reported in placebo-controlled trials: akathisia and nausea (each in more than 3% of patients on oral aripiprazole).International label, equivalent formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to aripiprazole or to any of the excipients.International label, equivalent formulation · European Medicines Agency (EPAR product information)

• Suicidal behaviour is inherent in psychotic and mood disorders and has been reported early after starting or switching antipsychotics; closely supervise high-risk patients.International label, equivalent formulation · European Medicines Agency (EPAR product information)
• Use with caution in cardiovascular or cerebrovascular disease, conditions predisposing to hypotension, or hypertension; identify venous thromboembolism risk factors; caution with family history of QT prolongation.International label, equivalent formulation · European Medicines Agency (EPAR product information)

• Strong CYP3A4 or CYP2D6 inhibitorsReduce the aripiprazole dose; increase it again when the inhibitor is withdrawn.European Medicines Agency (EPAR product information)
• Strong CYP3A4 inducersIncrease the aripiprazole dose; reduce to the recommended dose when the inducer is withdrawn.European Medicines Agency (EPAR product information)

• No adequate well-controlled studies in pregnant women; should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.International label, equivalent formulation · European Medicines Agency (EPAR product information)
• Aripiprazole/metabolites are excreted in human milk; decide whether to stop breast-feeding or the therapy, weighing benefits for child and mother.International label, equivalent formulation · European Medicines Agency (EPAR product information)

• Aripiprazole: Mechanism in schizophrenia and bipolar I disorder is not fully known; efficacy may be mediated by partial agonism at dopamine D2 and serotonin 5-HT1A receptors combined with antagonism at 5-HT2A receptors (US prescribing information).